BIRC5 and neuroendocrine neoplasm: Several peptide vaccines targeting survivin, including SurVaxM, demonstrated safety and immunogenicity in early-phase trials for glioblastoma and neuroendocrine tumors, although their efficacy was restricted to specific HLA haplotypes (HLA-A∗02, A∗03, or A∗24).